Abbott Laboratories (NYSE: NYSE:ABT) has demonstrated resilience and growth potential in the healthcare sector, maintaining a strong financial profile despite facing various challenges. According to ...

Abbott's Q4 sales grow 7.2%, missing estimates, but analysts remain upbeat with strong 2025 projections driven by Diabetes ...

From medical devices to OTC drugs, preemption to expert preclusion, New York state and federal courts issued decisions in ...

Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target of ...

Stifel Nicolaus analyst Rick Wise maintained a Buy rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target of ...

It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...

CEO Robert Ford also plans to expand sales of the company’s Lingo over-the-counter glucose sensors after a limited rollout.

For 2025, Abbott forecast organic sales growth of between 7.5% and 8.5%, as well as adjusted earnings per share of $5.05 to $5.25. Analysts expect $5.16 a share on $42 billion in sales.

Abbott Laboratories on Wednesday forecast first-quarter profit below Wall Street as weakness in nutrition and diagnostics ...

The company's fourth-quarter sales reached $11.0 billion, showing an increase of 7.2 percent on a reported basis and 8.8 ...

Abbott reported fourth-quarter results that missed the consensus sales forecast — but medical device sales remain a bright ...